Biomarin Pharmaceutical is a biotechnology business based in the US. Biomarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Biomarin Pharmaceutical employs 3,082 staff and has a trailing 12-month revenue of around $2.2 billion.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $86.27 |
|---|---|
| 52-week range | $80.53 - $117.77 |
| 50-day moving average | $89.37 |
| 200-day moving average | $96.88 |
| Wall St. target price | $117.18 |
| PE ratio | 170.8077 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.52 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $86.27 from 2023-09-21
| 1 week (2023-09-15) | -2.14% |
|---|---|
| 1 month (2023-08-22) | -4.71% |
| 3 months (2023-06-22) | -9.77% |
| 6 months (2023-03-18) | N/A |
| 1 year (2022-09-22) | 1.59% |
|---|---|
| 2 years (2021-09-22) | 9.16% |
| 3 years (2020-09-22) | 8.71% |
| 5 years (2018-09-21) | 97.84 |
Valuing Biomarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biomarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $2.2 billion |
|---|---|
| Operating margin TTM | 4.15% |
| Gross profit TTM | $1.6 billion |
| Return on assets TTM | 0.91% |
| Return on equity TTM | 2.15% |
| Profit margin | 4.47% |
| Book value | $25.42 |
| Market Capitalization | $16.7 billion |
TTM: trailing 12 months
We're not expecting Biomarin Pharmaceutical to pay a dividend over the next 12 months.
Over the last 12 months, Biomarin Pharmaceutical's shares have ranged in value from as little as $80.53 up to $117.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomarin Pharmaceutical's is 0.3607. This would suggest that Biomarin Pharmaceutical's shares are less volatile than average (for this exchange).
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U. S.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.